Acute coronary syndrome (ACS) is an umbrella term describing the clinical presentation of acute myocardial ischemia, most commonly due to sudden coronary artery thrombosis superimposed on underlying atherosclerosis. It includes ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina. Despite varying electrocardiographic and biomarker patterns, these entities share a unifying pathophysiologic mechanism: an abrupt mismatch between myocardial oxygen supply and demand, typically triggered by plaque rupture and activation of platelets and the coagulation cascade.
The pathogenesis begins with vulnerable atherosclerotic plaques in coronary arteries. Plaque rupture or erosion exposes thrombogenic material, leading to platelet adhesion, activation, and aggregation, with thrombin generation and fibrin formation. The resulting thrombus may partially occlude the vessel or completely block it, causing ischemia and, if sufficiently prolonged, necrosis. Clinically relevant risk factors include age, male sex, smoking, diabetes mellitus, hypertension, dyslipidemia, chronic kidney disease, obesity, sedentary lifestyle, and a history of coronary artery disease.
A central clinical feature of ACS is chest discomfort, which may present as pressure, tightness, heaviness, or pain that can radiate to the arm, jaw, back, or epigastrium. Symptoms can also be atypical, especially in women, older adults, and patients with diabetes—manifesting as dyspnea, diaphoresis, fatigue, nausea, or syncope. Associated autonomic symptoms reflect sympathetic activation and catecholamine release during ischemia.
Diagnosis is time-sensitive and guided by immediate risk stratification. Initial evaluation includes a rapid 12-lead electrocardiogram and serial cardiac biomarkers, particularly high-sensitivity troponin, which detects myocardial injury. STEMI is characterized by persistent ST-segment elevation meeting established criteria, whereas NSTEMI typically shows less specific ECG changes (e.g., ST depression, T-wave inversion) with troponin elevation. Unstable angina typically presents with ischemic symptoms and ECG changes without troponin rise, though contemporary practice recognizes that very small troponin elevations can blur boundaries.
Biomarker interpretation requires careful attention to timing and assay characteristics. Troponin elevations indicate necrosis, whereas absence of troponin rise suggests reversible ischemia. In addition to biomarkers and ECG, clinicians may use risk scores (e.g., TIMI or GRACE) to estimate the probability of adverse events and to tailor management intensity.
Management is defined by rapid restoration of coronary perfusion and prevention of further thrombosis. For STEMI, prompt reperfusion is prioritized via primary percutaneous coronary intervention, or fibrinolysis when PCI is not timely. For NSTEMI and unstable angina, early invasive strategies are often employed for higher-risk patients, alongside antithrombotic therapy. Core pharmacotherapy typically includes antiplatelet agents (aspirin, and a P2Y12 inhibitor), anticoagulation (e.g., unfractionated heparin or low-molecular-weight heparin), and anti-ischemic medications such as nitrates, beta-blockers, and high-intensity statins. Adjunctive therapies may include oxygen only when hypoxemia is present, morphine for severe pain with caution, and guideline-directed dual antiplatelet therapy duration based on bleeding risk.
Secondary prevention is essential to reduce recurrent events. This includes aggressive lipid lowering with statins and, when needed, additional agents such as ezetimibe or PCSK9 inhibitors; blood pressure control; smoking cessation; structured physical activity; weight management; and diabetes optimization. Evidence-based therapies also include ACE inhibitors or ARBs in selected populations (e.g., with reduced left ventricular function, diabetes, or other indications), and mineralocorticoid receptor antagonists when appropriate.
Complications of ACS range from arrhythmias and cardiogenic shock to heart failure, mechanical complications (e.g., papillary muscle rupture, ventricular septal defect), and recurrent ischemia. Continuous monitoring in an appropriate setting is therefore standard. Patient education focuses on recognizing warning symptoms, adherence to antithrombotic regimens, and follow-up for functional assessment and risk-factor modification.
In summary, ACS is a medical emergency driven by acute coronary thrombosis and myocardial ischemia. Timely ECG and serial troponin testing, followed by reperfusion when indicated and comprehensive antithrombotic and anti-ischemic therapy, improves outcomes. Long-term secondary prevention targets the atherosclerotic process and residual risk to prevent future myocardial infarction and cardiovascular mortality.
Source: Finsee_main (X post)
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
